Rokit Healthcare (376900.KQ) has signed a supply agreement with a Saudi Arabian medical company for its chronic kidney disease (CKD) prediction artificial intelligence (AI) platform, moving to tap the Middle East digital healthcare market.
The AI-based hyper-personalized organ regeneration platform company said Wednesday that it has signed a "technology license and access agreement" with Saudi Arabian medical firm LifeHope.
Under the deal, Rokit Healthcare will provide its CKD prediction AI algorithm by integrating it into LifeHope's "Longevity Platform." The contract is structured as a non-exclusive, non-transferable license limited to Saudi Arabia. Rokit Healthcare will receive 20% of the platform's net sales as royalties.
LifeHope is the owner of Albayat Medical Tower in Saudi Arabia. The company plans to cooperate with Rokit Healthcare to ensure the platform's smooth deployment in the Saudi medical market by linking it with the hospital network and insurance reimbursement system within Saudi Arabia's HEALTH SOCIETY system.
"The test price is set at around $100 per case, reflecting the characteristics of the Middle East premium medical market and hospital-based prediction and testing services," a Rokit Healthcare official said. "The actual pace of market formation and revenue scale may vary depending on hospital adoption, insurance coverage, local regulatory approval, testing demand, and the partner's sales capabilities."
Saudi Arabia is a market with significant potential demand for CKD prediction and testing services, driven by high prevalence rates of chronic conditions such as diabetes and hypertension. It is also expected to hold strategic value as a gateway for expansion across the Middle East and North Africa (MENA) region. Starting with this agreement, Rokit Healthcare plans to expand into other Gulf Cooperation Council (GCC) countries, including the United Arab Emirates (UAE), Qatar, and Kuwait.
Rokit Healthcare's core business is an organ regeneration platform that combines medical wound modeling AI, disposable regeneration kits, hyper-personalized bioinks, and medical 3D bioprinters. The company has recently expanded its business scope to include predicting CKD in advance and establishing customized management strategies based on those predictions.
